Effects of posterior vitreous detachment status on visual and anatomic outcomes after diabetic vitrectomy by Palvadi, Karishma
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018
Effects of posterior vitreous
detachment status on visual and
anatomic outcomes after diabetic
vitrectomy
https://hdl.handle.net/2144/31258
Boston University
	 	 	
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
EFFECTS OF POSTERIOR VITREOUS DETACHMENT STATUS 
 
ON VISUAL AND ANATOMIC OUTCOMES AFTER DIABETIC VITRECTOMY 
 
by 
 
 
KARISHMA PALVADI 
 
B.S., Baylor University, 2016 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2018  
	 	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2018 by 
 Karishma Palvadi 
 All rights reserved  
	 	 	
Approved by 
 
 
First Reader   
 Jean L. Spencer, Ph.D. 
 Instructor of Biochemistry  
 
 
 
Second Reader   
 Jorge G. Arroyo, M.D., M.P.H. 
 Associate Professor of Ophthalmology  
 Harvard Medical School 
 
 
		 iv 
DEDICATION 
 
 
I would like to dedicate this to my family, who have stood by me and never 
stopped believing in me. Your support means the world to me. 
 
 
  
		 v 
ACKNOWLEDGMENTS 
 
I wish to thank Dr. Jorge Arroyo for the opportunity to participate in his research 
and clinic. I am grateful to have had the opportunity to be able to learn from him 
and everyone else at BIDMC Eye Center. I would also like to thank Dr. Peng Sun 
and Rachel Tandias for their help and guidance. Thank you all.  
 
  
		 vi 
EFFECTS OF POSTERIOR VITREOUS DETACHMENT STATUS 
 
ON VISUAL AND ANATOMIC OUTCOMES AFTER DIABETIC VITRECTOMY 
KARISHMA PALVADI 
ABSTRACT 
Purpose: This study examined the surgical outcomes after pars plana vitrectomy 
in patients with proliferative diabetic retinopathy at various stages of posterior 
vitreous detachment. The investigation assessed the changes in visual acuity 
and the frequency of complications associated with each stage of detachment.  
Methods: This retrospective, single-site, single-surgeon study reviewed 328 
medical records of patients at Beth Israel Deaconess Medical Center (Boston, 
MA) requiring pars plana vitrectomy (PPV) for complications of proliferative 
diabetic retinopathy between 2000 and 2017. The 328 patients were separated 
into 4 groups based on their vitreous status (Stages 0 and 1, Stage 2, Stage 3, 
and Stage 4).  Preoperative characteristics were collected, including best-
corrected visual acuity (BCVA) and diabetes duration. Complications, visual 
acuity, and reoperation data were collected postoperatively.  
Results: Sixty-one percent of the patients in the combined group (Stages 0 and 
1), 56% in Stage 2, 67% in Stage 3, and 77% in Stage 4 did not require a 
revision PPV. Thirteen percent of the patients in the combined group, 13% in 
Stage 2, 5% in Stage 3, and 0% in Stage 4 required a revision PPV for retinal 
detachment. This represented a statistically significant difference between the 
groups (p = 0.0254). The combined group had a postoperative change in BCVA 
		 vii 
of 0.31 compared with 0.29 for Stage 2, 0.67 for Stage 3, and 0.90 for Stage 4. 
These BCVA changes represented a statistically significant difference (p = 
0.0001) between the groups.  
Conclusions: This study shows that having a preoperative posterior vitreous 
detachment leads to improved visual acuity postoperatively and decreased 
chance of developing a postoperative retinal detachment. The study also 
indicates that increased vitreoretinal traction results in less change in visual 
acuity and an increase in complications. Further research is needed to validate 
these findings.  
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INTRODUCTION 
Anatomy of the Human Eye 
The human eye is crucial for our sense of sight and functions to connect 
our brain to the outside world. The globe can be broken down into three basic 
layers (Figure 1). The outermost layer is protective and made up of the sclera 
and cornea. The sclera functions as a site of attachment for extraocular muscles, 
maintains intraocular pressure, and helps retain the shape of the eye (Malhotra, 
Minja, Crum, & Burrowes, 2011; Willoughby et al., 2010). The cornea is the most 
densely innervated tissue in the body and is avascular. It functions to transmit 
light to the lens and the retina (Willoughby et al., 2010). The middle layer is a 
vascular layer and consists of the ciliary body, choroid, and iris. The iris 
separates the anterior compartment of the eye into anterior and posterior 
chambers and controls the size of the pupil (Malhotra et al., 2011; Willoughby et 
al., 2010). The ciliary body controls the shape of the lens and produces the 
aqueous humor. The choroid provides oxygen and nutrients to the outer layers of 
the retina (Willoughby et al., 2010).  
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The innermost layer is the retina, which consists of ten parallel layers. 
They are the inner limiting membrane, nerve fiber layer, ganglion cell layer, inner 
plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, 
outer limiting membrane, photoreceptor layer, retinal-pigmented epithelium, and 
choroid. The retinal pigmented epithelium (RPE) is a single layer of cells that are 
connected to each by tight junctions forming a retinal-blood barrier (Malhotra et 
al., 2011). The function of the RPE is to maintain the photoreceptors, store 
vitamin A, and produce growth factors for nearby tissue (Willoughby et al., 2010).  
Figure 1. Anatomy of the eye. The illustration shows the three layers of 
the eye. The outer protective layer consisting of the sclera and cornea, the 
vascular middle layers, and the innermost layer, which is the retina. 
Adapted from Willoughby et al., 2010. 
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The retina is made up of six main classes of neurons: photoreceptors, 
bipolar cells, horizontal cells, amacrine cells, ganglion cells, and Müllerian glia 
(Figure 2).  
 
Figure 2. Layers of the retina. This image illustrates the layers of the 
retina.The layers are the inner limiting membrane (ILM), ganglion cell 
layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer 
plexiform layer (OPL), outer nuclear layer (ONL), outer limiting 
membrane (OLM), and the photoreceptor layer. The ILM contains the 
end of the Muller cells where they attach to retinal vasculature. The GCL 
contains ganglion cells. The IPL contains the synapses between the 
bipolar cells and the ganglion and amacrine cells. The OPL contains the 
ends of the rods (spherules) and the cones (pedicles). The ONL houses 
the cell bodies of the rods and cones. Adapted from Kolb et al., 2007. 
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There are two types of photoreceptors, rods and cones, which are 
responsible for converting light into an electrical signal. Rods are twenty times 
more common than cones, except at the fovea, which has the greatest density of 
cones and is responsible for sharp central vision (Willoughby et al., 2010). At the 
optic disk there are no rods or cones, and this area represents the blind spot in 
the visual field (Malhotra et al., 2011). The vitreous body is contained between 
the retina and the lens and makes up two-thirds of the volume of the eye. The 
vitreous mostly consists of water (98%-99%), collagen fibrils, soluble proteins, 
salts, and hyaluronic acid (Malhotra et al., 2011). The vitreous is attached to the 
retina at the ora serrata and the optic disk. It is also attached to the ciliary 
epithelium at the pars plana. These attachments are strong, but they weaken 
with age as the vitreous liquefies. The lens is a transparent, biconcave structure 
that refracts light and separates the aqueous humor from the vitreous (Malhotra 
et al., 2011).  
 
Proliferative Diabetic Retinopathy 
Diabetes mellitus has cemented its position as a worldwide epidemic 
because of the increasing number of diagnoses each year (Zimmet, Alberti, & 
Shaw, 2001). Diabetes is a disease of long-term hyperglycemia leading to 
microvascular damage of which diabetic retinopathy is the most common. It has 
been shown that diabetic retinopathy is the most prevalent cause of acquired 
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blindness in the USA with 12,000-24,000 cases of legal blindness reported 
annually (Danis & Davis, 2008). The hyperglycemia alters the biochemistry and 
hemodynamics of the vasculature leading to capillary occlusion and hypoxia. The 
retina has the highest oxygen demand of any tissue in the body because it is 
extremely metabolically active. Hypoxia leads to the upregulation of other 
pathways and proteins such as vascular endothelial growth factor (VEGF). VEGF 
mediates the formation of new blood vessels and increases vascular permeability 
by changing the conformation of the tight junctions in the retinal vascular 
endothelial cells. Intercellular adhesion molecule-1 (ICAM-1) and protein kinase 
C-beta (PKC-beta) are also involved in increasing vascular permeability and 
changing retinal circulation (Danis & Davis, 2008).  
Diabetic retinopathy can be classified as either non-proliferative diabetic 
retinopathy (NPDR) or proliferative diabetic retinopathy (PDR). Diabetic 
retinopathy is classified as NPDR if microaneurysms and intraretinal 
abnormalities are present (Figure 3). NPDR itself can be divided into four stages: 
mild, moderate, severe, and very severe. In mild and moderate NPDR there are 
few intraretinal hemorrhages and microaneurysms. The severe stage has 
increasing retinal ischemia and is diagnosed by analyzing the quadrants of the 
mid-peripheral retina using the 4-2-1 rule. The 4-2-1 rule refers to having any one 
of the following: extensive intraretinal hemorrhages and microaneurysms in all 
four quadrants, venous beading in two or more quadrants, or intraretinal 
microvascular abnormalities (IRMA) in one or more quadrants (Danis & Davis, 
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2008). If two or more of these conditions are present, the classification of very 
severe NPDR is used. Advanced NPDR leads to nonperfusion, which will 
eventually progress to PDR. The classification of PDR is defined by the growth of 
new blood vessels, known as neovascularization. Macular edema is prevalent in 
both PDR and NPDR as a result of the increased presence of VEGF, which 
breaks down the endothelial tight junctions and leads to the loss of the blood-
retinal barrier. Having very severe NPDR increases the risk of developing high-
risk PDR in one year by 60-fold. Poor blood glucose control, elevated 
triglycerides, low high-density lipoproteins (HDL), and pregnancy are all risk 
factors for progression of diabetic retinopathy (Danis & Davis, 2008).  
 
Figure 3. Fundus photograph of NPDR. The image shows cotton-wool spots 
(2), intraretinal microvascular abnormalities (3), and a blot hemorrhage (1). The 
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arrows refer to soft exudates. NPDR = non-proliferative diabetic retinopathy. 
Adapted from Danis & Davis, 2008.  
PDR is characterized by neovascularization on the surface of the retina 
(Figure 4). Neovascularization usually grows above the internal limiting 
membrane (ILM) on the interface between the retina and the posterior surface of 
the vitreous. This condition develops because the new vessels need a scaffold 
on which to grow; therefore, neovascularization does not frequently occur in 
areas where the vitreous has already detached or been removed surgically 
(Danis & Davis, 2008). The new vessels are most often seen near and on the 
optic disk and form round vascular networks reminiscent of wheels. They contain 
a multitude of cell types including pericytes, fibrocytes, macrophages, and glial 
cells. These lesions of neovascularization operate in cycles of growth and partial 
to total regression. Often the proliferation will contract, leading to the known 
complications of PDR. New vessels are generally asymptomatic until the 
beginning stages of a posterior vitreous detachment (PVD). When a patient has a 
symptomatic vitreous hemorrhage, it is usually accompanied by PVD (Danis & 
Davis, 2008).  
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Figure 4. Fundus photograph of PDR. The image shows the formation of new 
vessels (2) and some wheel-like networks (1) characteristic of PDR (proliferative 
diabetic retinopathy). Adapted from Danis & Davis, 2008.  	
PVD normally begins near the posterior pole and spreads within weeks to 
the edge of the quadrant in which it started. Subsequent spreading into the other 
quadrants is slower and may take months to years. In PDR, the vitreous stays 
attached to the disk because of adhesions between the vitreous and the 
proliferations on the disk. Vitreous detachment happens in discrete steps, rather 
than as a smooth process, because the separation stops whenever a patch of 
proliferation is encountered. There is no traction on the retina if the new vessels 
are only on the disk, but the vitreous probably does not detach from the disk 
(Danis & Davis, 2008). The vitreous pulling on the patches of neovascularization 
can lead to recurrent vitreous hemorrhages. When the vitreous detaches to the 
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point where there is no longer any traction or if the PDR enters the burned-out 
stage, vitreous hemorrhaging may stop. The traction from the vitreous on areas 
of retinal neovascularization can also lead to a retinal detachment. The timing 
and degree of the shrinkage of the vitreous and proliferations, as well as the 
location of the adhesions, affect the chance of a retinal detachment. For 
example, if new vessels have little fibrous tissue around them and a PVD starts 
soon after the beginning of neovascularization, it is likely that the vitreous will 
evulse the neovascularization thereby relieving the vitreoretinal traction (Danis & 
Davis, 2008). PDR enters the burned-out stage when the vitreous is finished 
contracting and has detached from all areas other than where new vessels 
prevent detachment. When this happens, vitreous hemorrhages will decrease in 
severity and frequency. Having a longer duration of diabetes is assoiated with a 
higher chance of developing diabetic retinopathy. It is more common for type 1 
diabetics to develop PDR, although type 2 diabetics who have unrecognized 
hyperglycemia for several years are at a higher risk (Danis & Davis, 2008).  
Visual loss associated with PDR is due to retinal ischemia, vitreous 
hemorrhage, and tractional retinal detachment. The process starts with 
neovacularization of the disk and retina. The growth of these new vessels 
happens at the same time as the fibroblast proliferation that uses the posterior 
hyaloid for support for growth. The contractions of these membranes lead to 
vitreous or subhyaloid hemorrhages. The traction can lead to traction retinal 
detachment (TRD) (Danis & Davis, 2008).  
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Treatments 
 Panretinal photocoagulation (PRP) is currently the main treatment for 
proliferative diabetic retinopathy.  The procedure is usually done in the office 
using an indirect ophthalmoscope to visualize the retina through a dilated pupil. 
In PRP, strong-intensity, large-sized burns are placed in the mid-peripheral retina 
360 degrees around (Figure 5). This process does not directly target the new 
vessels, but the new vessels regress in approximately six weeks. The reason 
behind the regression may be decreased VEGF production due to less ischemic 
retinal tissue and increased oxygen in the retina (Das, Stroud, Mehta, & 
Rangasamy, 2015). The procedure works by destroying the highly metabolically 
active photoreceptor cells, which allows the oxygen that would normally feed 
these cells to move into the lower layers and oxygenate them (Sabrosa, Sabrosa, 
Gouvea, & Gonçalves Filho, 2013). PRP was found to reduce the risk of severe 
vision loss by about 50% over five years. The complications of PRP include 
worsening macular edema, impaired peripheral retinal function, and impaired 
night vision (Das et al., 2015).  
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Figure 5. Effects of PRP over seven months. Image A shows 
neovascularization with scatter photocoagulation. Image B was taken four 
months later and indicates an increase in neovascularization and the presence of 
fibrous tissue. Image C was taken seven months later. The fibrous tissue has 
contracted, causing the retina to detach as a result of the adhesion between the 
two tissues. PRP = Panretinal photocoagulation. Adapted from Danis & Davis, 
2008.  
  
Another treatment for proliferative diabetic retinopathy is anti-VEGF 
antibodies injected into the vitreous (Figure 6). This procedure is done in the 
office under topical anesthesia. Some of the medications commonly used 
include: VEGF antibodies (bevacizumab), monoclonal antibody fragments 
(ranibizumab), and soluble proteins containing extracellular VEGF receptor 
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sequences (aflibercept). Anti-VEGF therapy causes rapid regression of retinal 
neovascularization and macular edema; however, the effects last only months. 
PRP combined with anti-VEGF therapy may be a good option to control PDR 
(Das et al., 2015).  
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Figure 6. Mechanism of hypoxia leading to neovascularization with sites of 
anti-VEGF action. This schematic shows how hypoxia leads to the release of 
VEGF, which results in angiogenesis. It also shows the location of action of the 
various anti-VEGF treatments. Adapted from Agarwal, Gelman, Prospero Ponce, 
Stevenson, & Christoforidis, 2015.  
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Despite the usage of PRP and anti-VEGF therapy, approximately 5% of 
eyes with PDR may need a pars plana vitrectomy (PPV) for non-clearing and 
recurrent vitreous hemorrhage and tractional retinal detachment (A. Gupta et al., 
2012). Dr. Robert Machemer first described the PPV procedure in 1972 using a 
14-gauge instrument. At that time the indications for PPV for patients with PDR 
were non-clearing vitreous hemorrhage (NCVH) which had not cleared for one 
year or traction retinal detachment (TRD) involving the macula (A. Gupta et al., 
2012). The purpose of a PPV is to separate the posterior surface of the vitreous 
from the ILM, thereby surgically creating a PVD. The current procedure more 
commonly uses 23-gauge, 25-gauge, or 27-gauge instruments because the 
smaller instruments require a smaller incision, leading to a faster recovery. A 
PPV requires three sclerotomies to be made and uses three main instruments: a 
light pipe, an infusion port, and a vitreous cutting device (Figure 7). Removing the 
vitreous improves visualization to the retina and allows retinal tears and breaks to 
be observed. Through this procedure, vitreous hemorrhage can be removed and 
traction can be released.  
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As shown in Figure 7, the vitreous is removed by first cutting it using the 
vitreous cutter and then removing it while infusing the eye with saline solution to 
maintain intraocular pressure (Recchia, Scott, & Brown, 2010). The light pipe is 
used to illuminate the interior of the eye. During the PPV, it is possible to perform 
photocoagulation, which can help stabilize proliferation (Sabrosa et al., 2013). 
The indication for surgery for a vitreous hemorrhage is a hemorrhage older than 
one-three months. Earlier surgery may be recommended for patients with 
aggressive fibrovascular proliferation, subhyaloid hemorrhage, TRD, neovascular 
glaucoma, and poor vision in the other eye. The indication for surgery for retinal 
detachment is dependent on the time since the onset of symptoms and whether 
Figure 7. Pars plana vitrectomy procedure. This image shows an 
example of a pars plana vitrectomy performed with three ports. One is 
used for the infusion cannula, one for the light pipe, and the last for the 
vitreous cutting device. Adapted from Spandau & Heimann, 2012.  
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the macula is involved (Sabrosa et al., 2013). Complications of PPV include rapid 
cataract formation, increased risk of glaucoma, retinal tear, retinal detachment, 
and infection (Recchia et al., 2010). Vitreous hemorrhage is a serious 
complication of PPV and is becoming more common as a result of patients with 
active PDR undergoing surgery more often (A. Gupta et al., 2012). According to 
Sabrosa et al. (2013), vitreous hemorrhage occurs in 22% of PDR patients who 
undergo vitrectomy, and neovascular glaucoma affects 20% of these patients.  
 
Posterior Vitreous Detachment  
Posterior vitreous detachment (PVD) refers to the separation of the 
posterior vitreous surface from the internal limiting membrane (ILM) of the retina. 
As the aging process occurs, the vitreous slowly liquefies, and about 50% is 
liquefied by the age of 70. Vitreous liquefaction, combined with the weakening of 
the interaction between the posterior vitreous face and the ILM, leads to the 
beginning of a PVD around the age of 40, with most occurrences being complete 
by the age of 60 (Simpson, Petrarca, & Jackson, 2012). Uchino, Uemura, and 
Ohba (2001) concluded that PVD starts with a detachment in one quadrant of the 
peripheral retina and then slowly extends to the other quadrants (Figure 8). Age-
related PVD is believed to be precipitated by a break in the posterior cortical 
vitreous that results in the liquefied vitreous passing into the subhyaloid space 
and causing the beginning of the separation of the vitreous from the retina 
(Johnson, 2010). If the patient does not have retinal vascular disease, this action 
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will quickly lead to a complete posterior vitreous detachment. PVD occurs at a 
faster rate in myopic and postmenopausal eyes. The final separation of the 
vitreous from the optic disk is usually symptomatic with the appearance of 
floaters and/or flashes of light. B-scan ultrasonography and optical coherence 
tomography (OCT) can detect shallow posterior hyaloid detachments (Johnson, 
2010). OCT is an imaging technique that uses the reflection of near-infrared light 
off tissues to create cross-sectional images. It does this by collecting the 
reflected light and measuring the differences in the time of flight. Deeper layers 
have a longer delay in reflected light (Costa, Skaf, Melo, Calucci, & Cardillo, 
2006). A B-scan is an ultrasonography technique that uses sound waves to 
produce an image of the internal portion of the eye. It is useful when the vitreous 
media is not clear, for example, during a vitreous hemorrhage or severe cataract, 
and a retinal detachment or PVD is suspected (Kendall et al., 2015).  
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Figure 8. OCT image showing early stages of vitreous separation. (A) 
Detachment is only detected at the arrow and is the earliest evidence of a PVD. 
(B) Detachment grows. (C) Adherence is observed at the foveola, but the rest of 
the macula is detached. (D) Detachment occurs throughout the macula. OCT = 
optical coherence tomography; PVD = posterior vitreous detachment. Adapted 
from Johnson, 2010.  
A
B	
C	
D	
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Because the posterior vitreous separates in discrete steps, there is a 
classification system of five steps (Figure 9). Stage 0 is defined as the absence 
of a PVD or the vitreous being firmly adherent to the retina. Stage 1 refers to the 
beginning of a PVD in one or more of the four quadrants with firm attachment to 
the macula and optic nerve. Stage 2 is defined as detachment at all four 
quadrants with persistent attachment to the macula and optic nerve. Stage 3 
refers to attachment only at the optic nerve. Stage 4 is defined as a complete 
posterior vitreous detachment with a Weiss ring (Uchino, Uemura, & Ohba, 
2001). A Weiss ring is the circular attachment of the vitreous to the optic nerve 
head, which only becomes visible after the complete detachment of the vitreous 
from the optic nerve (Figure 10). 
 
Figure 9. Stages of age-related PVD. These images illustrate the growing PVD: 
Stage 1 (some detachment in the mid-peripheral retina), Stage 2 (attachment at 
macula and optic nerve), Stage 3 (attachment only at optic nerve), and Stage 4 
(complete detachment). PVD = posterior vitreous detachment. Adapted from 
Johnson, 2010.  
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Posterior Vitreous Detachment In Diabetic Retinopathy 
According to Takahashi’s (1981) study, being older at the time of onset of 
diabetes is associated with complete vitreous detachment, and being younger at 
the time of onset is associated with partial vitreous detachment. In the study, only 
partial PVD was found in patients with PDR. Partial PVD is much more common 
in PDR than in NPDR, indicating that a partially detached vitreous plays a part in 
Figure 10. Complete PVD with Weiss ring. This image shows an eye that has 
undergone a complete PVD, which is evident by the presence of a Weiss ring. 
Weiss rings are only visible after the vitreous has detached from the optic nerve 
head. PVD = posterior vitreous detachment. Adapted from Kolb et al., 2007.  
	21 
proliferative changes. Proliferation is quicker in those patients with partial PVD 
(Takahashi, 1981).  
In PDR, retinal ischemia occurs because of capillary occlusion, and in 
response to this blockage, there are proliferative changes. The new vessels that 
form leak plasma proteins into the vitreous, causing the vitreous to contract and 
then start to separate from the underlying retina. Vitreous detachment due to 
diabetic retinopathy is not primarily a result of vitreous liquefaction, and the 
vitreous can still be solid. Partial vitreous detachment generally starts outside the 
retinal vascular arcades at sites of neovascularization. The new vessels are 
pulled forward by the contracting vitreous and continue to grow on the surface of 
the detached vitreous (Jalkh, Takahashi, Topilow, Trempe, & McMeel, 1982). 
Partial vitreous detachment is associated with severe fibrovascular proliferation 
and increases the risk of vitreous hemorrhage, traction retinal detachment, and 
retinal breaks. No vitreous detachment is associated with less severe PDR, and 
complete PVD is associated with mild retinopathy. Partial vitreous detachment 
with vitreous traction indicates a high risk that the PDR will progress. It is the firm 
adhesions between the fibrovascular tissue and the vitreous cortex that lead to a 
partial PVD (Jalkh et al., 1982). 
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SPECIFIC AIMS  
The primary goal of this retrospective single-site, single-surgeon study is 
to analyze how the various stages of posterior vitreous detachment (PVD) affect 
the outcomes of pars plana vitrectomy (PPV) in patients with proliferative diabetic 
retinopathy (PDR). The objective is to determine whether there is a statistically 
significant difference in surgical outcomes between the five stages of PVD based 
on reoperations, complications, and best-corrected visual acuities. This 
investigation, along with related vitreoretinal surgery publications, may provide 
vitreoretinal surgeons and patients with more detailed information on their 
chance of developing a complication and on their visual prognosis based on 
vitreous status.  
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METHODS  
 This retrospective clinical case series was conducted at Beth Israel 
Deaconess Medical Center in Boston, Massachusetts. Medical records were 
reviewed of a single surgeon’s patients to identify patients with proliferative 
diabetic retinopathy (PDR) who underwent pars plana vitrectomy (PPV) for 
complications of their PDR between May 2000 and August 2017. Patients with 
NPDR, previous PPV, and trauma were excluded. After the exclusion, three 
hundred and eighty-four eyes were left (n = 384). From the medical records, 
baseline and preoperative parameters were collected, including age, sex, eye 
(right or left), hemoglobin A1c (HbA1c), diabetes duration, past ocular surgeries, 
lens status, best-corrected visual acuity (BCVA), and previous anti-VEGF 
treatment. Intraoperative and postoperative measures were collected and 
included vitreous status, intraoperative retinal breaks, final BCVA, complications, 
and number, if any, of reoperations. All patients underwent 23- or 27-gauge 
three-port pars plana vitrectomy with combination of delamination and 
segmentation of tractional membranes. All patients had postoperative follow-up 
of at least three months.   
 
Preoperative Consult  
Prior to surgery, patients were seen by the physician to determine the 
diagnosis and discuss possible treatments. Diagnosis of vitreous hemorrhage or 
traction retinal detachment was made through dilated ophthalmoscopic 
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examination, OCT imaging and B-scan ultasonography. The treatment options of 
observation versus pars plana vitrectomy were discussed with the patient. After 
surgery was agreed upon, patients were informed of the one in one thousand risk 
of infection and bleeding with ocular surgery, which could lead to additional 
complications. They were also informed of the one in one hundred risk of the 
development of retinal tears or detachments during surgery, which would be fixed 
during the surgery if they occurred. In addition, patients who did not yet have 
cataracts were informed of the one hundred percent risk of developing cataracts 
in the year following surgery. The physician often recommended cataract 
extraction with posterior chamber intraocular lens placement simultaneously with 
PPV for patients who already had visually significant cataracts. Once the 
physician presented the indications and the risks and benefits of surgery, 
patients signed consent forms and were scheduled for surgery.    
 
Surgical Procedure 
On the day of surgery, each patient was brought to the operating room 
and connected to oxygen and blood pressure monitors as well as an 
electrocardiogram to monitor the patient’s vitals throughout the surgery. The 
operative eye was then draped and prepped in standard ophthalmic fashion, and 
a wire lid speculum was placed to keep the eye open during the surgery. The eye 
was anesthetized, and akinesia was produced by a retrobulbar infusion behind 
the eye of a 50:50 mixture of 2% lidocaine and 0.75% Marcaine with epinephrine 
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(Pfizer). Three sclerotomies were made 3.5 mm posterior to the limbus in the 
superonasal, superotemporal, and inferotemporal quadrants. The 4-mm infusion 
cannula was inserted into the inferotemporal sclerotomy and was inspected to 
ensure that it was properly placed in the vitreous cavity before infusion took 
place.  
Phacoemulsification and posterior chamber intraocular lens placement for 
cases requiring cataract extraction were performed and completed prior to 
vitrectomy. Kenalog dye (Bristol-Myers Squibb) was injected into the vitreous to 
stain the vitreous and the retina. Complete peripheral and central vitrectomy was 
then performed using the vitreous cutter and light pipe. If during vitrectomy the 
posterior hyaloid was noted to be still attached to the retina, the vitreous cutter 
was set to aspiration to peel the posterior hyaloid off the surface of the retina and 
the macula to ensure that a good peripheral vitrectomy could be performed. 
When necessary, endolaser photocoagulation was applied to the retina.           
If an epiretinal membrane (ERM) was present, it was stained using 
Kenalog and peeled off the macula using ILM forceps. For cases in which the 
ILM was peeled, indocyanine green (ICG) was used to stain the ILM for varying 
durations. Next, the ILM was grasped using the ILM forceps, and an edge was 
created in the ILM. The ILM was then completely peeled off the macula and the 
fovea in a 360-degree circular fashion. After the ILM was peeled, a 360-degree 
scleral depressed examination was performed to check for evidence of retinal 
tears or detachments. If any tears or detachments were noted, they were fixed at 
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this time. The sclerotomies were then closed and checked to ensure that they 
were watertight. The intraocular pressure was checked, and a subconjunctival 
injection of Kefzol (Eli Lilly) and dexamethasone was given. The operative eye 
was patched with a drop of 0.25% scopolamine, bacitracin ointment, a soft eye 
pad, and a hard eye shield. The patient was then brought back to the recovery 
room. On postoperative day one, the patient followed up to have the patch 
removed and was given instructions for proper application of topical eye drops 
and ointment.  
 
Logarithm of Minimum Angle of Resolution (LogMAR) 
The LogMAR scale is used when comparing visual acuities as it allows 
several visual acuity measurements to be analyzed at once. In this study, visual 
acuities were converted to logMAR units from Snellen units in order to compare 
preoperative and postoperative best-corrected visual acuities (BCVAs) between 
the groups (Holladay, 1997). The following equation (Equation 1) was used for 
the conversion:  
 LogMAR = -Log(20/Distance of best line read in feet) (1)  
where the visual acuity in parentheses represents the Snellen visual acuity 
associated with the lowest line read when checking vision. Table 1 provides the 
values used in this study.  
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Table 1. Conversion Between Vision Acuity in Feet and LogMAR Score  
Snellen Visual Acuity (Feet)a LogMARb 
Light perception (LP)c 2.60 
Hand motions (HM) 2.30 
Count fingers (CF) 1.85 
20/400 1.30 
20/200 1.00 
20/150 0.88 
20/100 0.70 
20/80 0.60 
20/70 0.54 
20/60 0.48 
20/50 0.40 
20/40 0.30 
20/30 0.18 
20/25 0.10 
20/20 0.00 
 
aDefined as person’s visual ability as measured in office setting. 
bCalculated by Equation 1. 
cLP = eye only detects light; HM = eye detects hand motions only; CF = eye can 
count fingers at a distance closer than the visual acuity chart.  
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Statistical Analyses  
Statistical analyses were performed through an analysis of variance 
(ANOVA) test to compare changes in best-corrected visual acuity (BCVA) values 
between the groups. Chi-squared tests were also performed to analyze the 
differences between complication rates between the groups. Statistical analyses 
were considered significant with a p-value less than 0.05.  
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RESULTS 
Preoperative Characteristics  
After the 384 medical records were reviewed, 56 cases were excluded 
because they lacked the required minimum follow-up of three months.The 
remaining 328 cases were separated into four groups based on vitreous status: a 
combined group containing Stages 0 and 1 (n = 94), Stage 2 (n = 140), Stage 3 
(n = 42), and Stage 4 (n = 52). Stages 0 and 1 were combined as a result of 
difficulty in differentiating between the stages retrospectively. Table 2 
summarizes the preoperative characteristics of the 328 patients. Stage 4 had a 
mean age of 67.6 years with an age range of 39-90 and a preoperative best-
corrected visual acuity (BCVA) of 1.55 ± 0.10 (mean ± standard error of mean). 
Stage 3 had a mean age of 62 years with an age range of 35-83 and a 
preoperative BCVA of 1.35 ± 0.13. Stage 2 had a mean age of 57.4 years with an 
age range of 31-89 and a preoperative BCVA of 1.36 ± 0.07. The combined 
group (Stages 0 and 1) had a mean age of 58.5 years with an age range of 28-87 
and a preoperative BCVA of 1.38 ± 0.08. There was a statistically significant 
difference between the mean ages of the groups (p < 0.001) and post-hoc 
pairwise comparisons between the ages of all of the groups (p < 0.01).  
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Table 2. Preoperative Characteristics of PDR Patients Undergoing PPV (n = 328) 
 Stages 0 &1 
(n = 94) 
Stage 2 
(n = 140) 
Stage 3 
(n = 42) 
Stage 4 
(n = 52) 
Age (years) 
Mean 58.5 57.4 62.0 67.6 
Range 28-87 31-89 35-83 39-90 
Sex 
Male 47 (50%)b 72 (51%) 22 (52%) 23 (44%) 
Female 47 (50%) 68 (49%) 20 (48%) 29 (56%) 
Eye 
Right 45 (48%) 68 (49%) 23 (55%) 24 (46%) 
Left 49 (52%) 72 (51%) 19 (45%) 28 (54%) 
Lens Statusc 
Phakic 67 (71%) 86 (61%) 27 (64%) 29 (56%) 
Pseudophakic 20 (21%) 30 (21%) 9 (21%) 19 (37%) 
Aphakic 0 (0%) 1 (0.7%) 0 (0%) 0 (0%) 
BCVA 
(LogMAR)d 
1.38 ± 0.08e 1.36 ± 0.07 1.35 ± 0.13 1.55 ± 0.10 
Diabetes Duration (years) 
<5 3 (3%) 3 (2%) 0 (0%) 1 (2%) 
>5 3 (3%) 10 (7%) 0 (0%) 2 (4%) 
>10 6 (6%) 12 (9%) 8 (19%) 3 (6%) 
>15 57 (61%) 73 (52%) 16 (38%) 37 (71%) 
Average HbA1c (%)f 8.5 7.8 8.8 8.0 
Anti-VEGF Treatment 25 (27%) 26 (19%) 4 (10%) 18 (35%) 
 
aPDR = proliferative diabetic retinopathy; PPV = pars plana vitrectomy; n = total number of 
patients undergoing surgery.  
bValues represent number of patients in stage with characteristic (percentage of total patients in 
stage). 
cPhakic = eye with natural lens; pseudophakic = eye with artificial lens; aphakic = eye with no 
lens. 
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dBCVA (LogMAR) = best-corrected visual acuity measured in LogMAR units. 
eValues represent mean ± standard error of mean. 
fHbA1c (%) =% glycated hemoglobin.  
 
Outcomes 
Table 3 summarizes the outcomes of the PPV for PDR complications. For 
Stage 4 (n = 52), 12 patients (23%) required a revision PPV for a complication, of 
whom 8 patients (15%) needed a reoperation for a vitreous hemorrhage (VH). 
The BCVA was 0.65 ± 0.08, representing a BCVA change of 0.90. For Stage 3 (n 
= 42), 14 patients (33%) required a revision PPV, of whom 2 patients (5%) were 
for retinal detachment (RD) and 9 patients (21%) were for vitreous hemorrhage 
(VH). The BCVA was 0.68 ± 0.11, representing a BCVA change of 0.67. For 
Stage 2 (n = 140), 61 patients (44%) required a revision PPV, of whom 18 
patients (13%) were for retinal detachment (RD) and 31 patients (22%) were for 
vitreous hemorrhage (VH). The BCVA was 1.06 ± 0.07, representing a BCVA 
change of 0.29. For the combined group (n = 94), 37 patients (39%) required a 
revision PPV, of whom 12 patients (13%) were for retinal detachment (RD) and 
19 patients (20%) were for vitreous hemorrhage (VH). The BCVA was 1.07 ± 
0.09, representing a change of 0.31. Figure 11 shows the changes in 
preoperative and postoperative BCVA values for all four groups undergoing PPV. 
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Table 3. Postoperative Measures of Patients with PDR Undergoing PPV (n = 328) 
 Stages 0 and 1 
(n = 94) 
Stage 2 
(n = 140) 
Stage 3 
(n = 42) 
Stage 4 
(n = 52) 
Reoperations 
0 57 (61%) 79 (56%) 28 (67%) 40 (77%) 
1-4 37 (39%) 61 (44%) 14 (33%) 12 (23%) 
Reoperation for RD 12 (13%) 18 (13%) 2 (5%) 0 (0%) 
Reoperation for VH 19 (20%) 31 (22%) 9 (21%) 8 (15%) 
Complicationsa 
Hypotony 1 (1%) 2 (1%) 0 (0%) 0 (0%) 
NVG 2 (2%) 11 (8%) 3 (7%) 3 (6%) 
Phthisis bulbi 1 (1%) 1 (0.7%) 1 (2%) 0 (0%) 
VH 40 (43%) 53 (38%) 10 (24%) 12 (23%) 
TRD/RRD 14 (15%) 18 (13%) 2 (5%) 0 (0%) 
FTMH 1 (1%) 2 (1%) 0 (0%) 0 (0%) 
ERM 6 (6%) 18 (13%) 4 (10%) 2 (4%) 
Glaucoma 8 (9%) 9 (6%) 4 (10%) 2 (4%) 
BCVA (post-op)b 
(LogMAR) 
1.07 ±0.09 1.06 ±0.07 0.68 ±0.11 0.65 ±0.08 
Change in BCVAc 0.31 0.30 0.67 0.90 
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Table 3. Postoperative Measures of Patients with PDR Undergoing PPV (n = 328) 
continued  
aHypotony = decreased intraocular pressure; NVG = increased intraocular pressure caused by 
the formation of new blood vessels; phthisis bulbi = shrunken eye can be due to many ocular 
conditions; VH = vitreous hemorrhage; TRD/RRD = combined form of retinal detachment due to 
diabetes; FTMH = full thickness macular hole; ERM = epiretinal membrane; glaucoma = 
increased intraocular pressure. 
bBCVA (post-op) = best-corrected visual acuity after surgery. 
cChange in BCVA = difference between preoperative and postoperative BCVA. 
 
 
 
 
 
 
 
 
 
 
Figure 11. Changes between preoperative and postoperative BCVA 
values after PPV. This illustrates the most significant change that occurred 
(Stage 4) and the least (Stages 0 and 1). BCVA = best-corrected visual 
acuity; PPV = pars plana vitrectomy.  
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Table 4. Statistical Analyses of Results  
 
Variable P-Valuea 
Mean age at time of surgery <0.001 
Reoperations 0.0649 
Reoperation for RDb 0.0254 
Reoperation for VHb 0.7771 
Complication rate for RD 0.0152 
Complication rate for VH 0.0383 
Preoperative BCVA 0.4571 
Postoperative BCVA 0.0012 
Change in BCVA 0.0001 
aStatistical significance: p < 0.05. 
bBCVA = best-corrected visual acuity; RD = retinal detachment; VH = vitreous 
hemorrhage; n = 328. 
 
Analysis 
The results of the statistical analyses are summarized in Table 4. The first 
analysis that was conducted was between the ages of the patients in the groups. 
An ANOVA test was used which resulted in a significant difference between the 
groups (p < 0.001). The second analysis conducted was to see if there was a 
statistically significant difference between the need for a revision PPV between 
the different groups. A chi-squared test was performed which resulted in a p-
value of 0.0649. When the revision PPV data was separated by the reason for 
the reoperation, there was a statistically significant difference between the 
groups for revision PPV for retinal detachment (RD) (p = 0.0254). The third 
analysis that was performed was to test whether there was a difference between 
the groups for different complications. These separate chi-squared tests resulted 
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in significant differences for complication rates for vitreous hemorrhage (VH) (p = 
0.0383) and retinal detachment (RD) (p = 0.0152). The fourth analysis that was 
performed was for best-corrected visual acuity (BCVA). ANOVA tests were 
performed on the preoperative BCVA values between the groups, the 
postoperative BCVA values between the groups, and the change in BCVA values 
between the groups. Two of the three tests yielded significant results, with 
postoperative BCVA values having a p-value of 0.0012 and change in BCVA 
values having a p-value of 0.0001.  
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DISCUSSION 
 Pars plana vitrectomy (PPV) is a surgical procedure that is used to treat 
the more complex complications of proliferative diabetic retinopathy (PDR), such 
as non-clearing vitreous hemorrhage (NCVH) or traction retinal detachment 
(TRD), and thereby improve vision. In this study of this procedure, the group with 
the oldest mean age (67.6 years) was the Stage 4 group, which is consistent with 
the physiology of age-related posterior vitreous detachment (PVD). Stage 4 also 
had 37% of its patients with previous cataract surgery and the highest logMAR 
preoperative vision of the groups. Postoperatively, 77% of the patients in Stage 4 
did not require a revision PPV, and of the 12 patients (23%) who did, 8 patients 
required it for a vitreous hemorrhage (VH). Stage 4 also had the largest change 
in BCVA (0.90). Stage 3 had a mean age of 62.0, and 21% of the patients had 
prior cataract surgery. Postoperatively, 67% of the patients in Stage 3 did not 
require a revision PPV, and of the 14 patients (33%) who did, 2 patients required 
it for retinal detachment (RD) and 9 for vitreous hemorrhage (VH). Stage 3 had 
the second highest change in BCVA at 0.67. Stage 2 had a mean age of 57.4, 
with 21% of the patients having had prior cataract surgery. Postoperatively, 56% 
of the patients did not require revision PPV, and 61 patients (44%) did, of which 
18 patients were for retinal detachment (RD) and 31 were for vitreous 
hemorrhage (VH). Stage 2 had the lowest change in BCVA at 0.29. The 
combined group (Stages 0 and 1) had a mean age of 58.5, and 21% of the 
patients had prior cataract surgery. Postoperatively, 61% of the patients did not 
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require revision PPV, and of the 37 patients (39%) who did 12 patients were for 
retinal detachment (RD) and 19 were for vitreous hemorrhage (VH). This group 
had the third highest change in BCVA at 0.31.  
 This retrospective clinical case series was performed to investigate 
whether vitreous status affects surgical outcomes, specifically visual acuity and 
reoperation rate. The patients who were included in the study (n = 328) were 
separated into four groups based on vitreous status. Preoperatively, the patients 
had the oldest mean age in Stage 4 and the youngest mean age in Stage 2. 
Also, the majority of patients in all of the groups were phakic (presence of eye’s 
natural lens), and in most cases posterior chamber intraocular lenses (PCIOL) 
placement was performed at the time of the PPV. In addition, most patients were 
diagnosed with diabetes mellitus over 15 years prior to surgery. The most 
common reason for PPV in this patient population was either NCVH or TRD. This 
is consistent with NCVH and TRD being the most frequently occurring 
complications of PDR (B. Gupta et al., 2012). Postoperatively, the results showed 
that the lowest chance of vitreous hemorrhage (VH) and retinal detachment (RD) 
and the best visual outcome were with a total vitreous detachment (Stage 4). The 
complication rates were higher with Stages 0 and 1 and Stage 2, showing that 
adherence to the retina increased the risk of complications and the need for 
repeat vitrectomies. Based on a search of the literature, there is no other study 
that analyzes the potential association between the stages of vitreous status and 
the outcomes of primary vitrectomy in proliferative diabetic retinopathy (PDR). 
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However, Kraus (2011) analyzed the effect of PVD on vitrectomy and membrane 
peel for epiretinal membrane (ERM) and found no significant difference in final 
visual outcomes associated with the presence or absence of a PVD.  
 The postoperative complication rate was the highest in the combined 
group (Stages 0 and 1), with 43% of the patients having a VH and 15% having an 
RD. The rate was lowest in the complete PVD group (Stage 4), with 23% of the 
patients having a VH and 0% having an RD. Schoenberger et al. (2011) reported 
complication rates of 38.7% for vitreous hemorrhage (VH), 4.6% for retinal 
detachment (RD), and 2.3 % for neovascular glaucoma. Min, Yihui, Hitam, and 
Ali (2017) also found complication rates of PPV at 11.7% for vitreous 
hemorrhage (VH) and 5.8% for retinal detachment (RD). The difference in 
complication rates between previous studies and this one can be partially 
explained by the separation of patients according to vitreous status in this study. 
 Min and colleagues (2017) addressed the statement that the worse 
preoperative vision generally leads to a greater postoperative BCVA. This is 
supported by the current study in which the Stage 4 group had the worst 
preoperative vision and the best postoperative vision.  
 The reoperation rates, although not statistically significant, were lower in 
the group with the complete PVD (Stage 4) compared with the other groups. The 
Diabetic Retinopathy Vitrectomy Study found that 19% of eyes required at least 
one additional vitrectomy (“Early Vitrectomy for Severe Vitreous Hemorrhage in 
	39 
Diabetic Retinopathy,” 1990). Our study had a comparable rate when the patient 
had a complete PVD and a higher rate when the vitreous was attached.  
 
Limitations 
Because this was a retrospective case series, the study was limited by the 
availability of data. Due to a lack of follow-up data, the study had 55 patients 
excluded from the analysis. In addition, the lack of patient compliance in follow-
up resulted in data from 1 to 5 years being used for the final visual acuity. This 
situation may have had an impact on the visual acuity results. Also, this case 
series did not separate patients based on preoperative diagnoses, and this 
condition may have impacted outcomes such as neovascular glaucoma, 
glaucoma, and retinal vein occlusions. Furthermore, vitreous status was 
identified by reading operative reports. More accurate classifications could be 
made in a future study if done prospectively with the surgeon noting the exact 
stage at the time of surgery. Another limitation was the small number of patients 
with a Stage 0 PVD, which led to the combination of Stages 0 and 1 for a more 
accurate analysis. The duration of diabetes was also self-reported by the patient 
in most cases, and this procedure may have made the information less reliable. 
Finally, a single surgeon operated on all of the patients, which may have been a 
confounding variable. A study involving the collaboration of many physicians 
would increase the number of patients and potentially increase the significance of 
the study.  
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Conclusions 
Having a complete PVD preoperatively (Stage 4) led to a decreased risk 
of complications and a better visual outcome. As the vitreous increasingly 
detached from the retina, the risk of complications decreased and the visual 
outcome improved. This information could be used to inform patients of their 
expected prognosis and to reassure them throughout their procedure. Future 
studies of diabetic vitrectomy should segregate patients based on vitreous status.  
Because this topic has not been widely studied, more research is needed to 
validate these findings.  
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